Quantisnow Logo
Dashboard

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

$BWAY
Medical/Dental Instruments
Health Care
Get the next $BWAY alert in real time by email

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:Tuesday, November 12, 2024
Time:8:30 AM Eastern Time
United States:1-877-300-8521
International:1-412-317-6026
Israel:1-80-921-2373
Conference ID:10193781
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1693565&tp_key=866e8470ea

The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company's website at least 10 minutes ahead of the conference call to register.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:

BrainsWay:

Ido Marom

Chief Financial Officer

Ido.Marom@BrainsWay.com

Investors:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com



Primary Logo

Get the next $BWAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New

  • When will BrainsWay report its third quarter 2024 financial results?

    BrainsWay Ltd. is scheduled to report its third quarter 2024 financial results on November 12, 2024, before U.S. markets open.

  • What time is the conference call scheduled for?

    The conference call will take place at 8:30 AM Eastern Time on November 12, 2024.

  • What are the dial-in numbers for the conference call?

    Investors can dial in to the conference call using the U.S. number 1-877-300-8521 or the international number 1-412-317-6026.

  • What is BrainsWay's area of expertise?

    BrainsWay specializes in advanced noninvasive neurostimulation treatments, particularly for mental health disorders, using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology.

  • Will the conference call be available for replay, and if so, for how long?

    The conference call will be accessible for replay for 30 days on BrainsWay's website after the live event.

Recent Analyst Ratings for
$BWAY

DatePrice TargetRatingAnalyst
11/16/2023Outperform → Mkt Perform
Raymond James
3/3/2022$15.00Buy
Loop Capital
11/29/2021$14.00 → $15.00Buy
HC Wainwright & Co.
8/12/2021$17.00 → $14.00Buy
HC Wainwright & Co.
7/19/2021$17.00Buy
HC Wainwright & Co.
More analyst ratings

$BWAY
 Press Releases

Fastest customizable press release news feed in the world

See more

  • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

    Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

    $BWAY
    Medical/Dental Instruments
    Health Care

  • BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

    BURLINGTON, Mass. and JERUSALEM, March 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference at 9:20 AM EST on March 18, 2025. A live webcast of the presentation will be available on the Events & News – Presentations page of the Company's Investor Relations website. An archived replay of the presentation will be available on the Company's website for 30 days following the live broadcast. Please contact your representativ

    $BWAY
    Medical/Dental Instruments
    Health Care

  • BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

    BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited

    $BWAY
    Medical/Dental Instruments
    Health Care

$BWAY
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BWAY
 SEC Filings

See more

$BWAY
 Leadership Updates

Live Leadership Updates

See more

  • BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

    BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

    $BWAY
    Medical/Dental Instruments
    Health Care

  • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

    Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

    $BWAY
    $INSG
    $MCK
    $NNDM
    Medical/Dental Instruments
    Health Care
    Telecommunications Equipment
    Telecommunications

  • BrainsWay Announces Appointment of Ido Marom as CFO

    BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i

    $BWAY
    Medical/Dental Instruments
    Health Care

$BWAY
 Financials

Live finance-specific insights

See more

  • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

    Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

    $BWAY
    Medical/Dental Instruments
    Health Care

  • BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

    BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited

    $BWAY
    Medical/Dental Instruments
    Health Care

  • BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

    Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided an operational update. Recent Financial and Operational Highlights For the three months ended September 30, 2024, revenues were $10.5 million, a 26% increase compared to the same period in 202

    $BWAY
    Medical/Dental Instruments
    Health Care

$BWAY
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more